Vertex Pharmaceuticals, Inc [VRTX] stock is trading at $457.36, down -1.25%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VRTX shares have gain 5.83% over the last week, with a monthly amount glided 8.46%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] stock has seen the most recent analyst activity on December 03, 2025, when Morgan Stanley upgraded its rating to an Overweight but kept the price target unchanged to $516 for it. Previously, Scotiabank started tracking the stock with Sector Outperform rating on November 13, 2025, and set its price target to $495. On September 25, 2025, upgrade upgraded it’s rating to Outperform but maintained its price target of $456 on the stock. Raymond James started tracking the stock assigning a Mkt Perform rating. Wells Fargo upgraded its rating to an Overweight but $460 remained the price target by the analyst firm on August 06, 2025. Wolfe Research downgraded its rating to Peer Perform for this stock on May 07, 2025. In a note dated May 06, 2025, Leerink Partners downgraded a Market Perform rating on this stock but restated the target price of $503.
Vertex Pharmaceuticals, Inc [VRTX] stock has fluctuated between $362.50 and $519.68 over the past year. Currently, Wall Street analysts expect the stock to reach $478.2 within the next 12 months. Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] shares were valued at $457.36 at the most recent close of the market. An investor can expect a potential return of 4.56% based on the average VRTX price forecast.
Analyzing the VRTX fundamentals
Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] reported sales of 11.73B for the trailing twelve months, which represents a growth of 12.27%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at 0.34%, Pretax Profit Margin comes in at 0.38%, and Net Profit Margin reading is 0.31%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.2 and Total Capital is 0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 452.70 points at the first support level, and at 448.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 462.86, and for the 2nd resistance point, it is at 468.36.
Ratios To Look Out For
For context, Vertex Pharmaceuticals, Inc’s Current Ratio is 2.36. Also, the Quick Ratio is 2.00, while the Cash Ratio stands at 1.1. Considering the valuation of this stock, the price to sales ratio is 9.89, the price to book ratio is 6.71 and price to earnings (TTM) ratio is 32.23.
Transactions by insiders
Recent insider trading involved JEFFREY M LEIDEN, Director, that happened on Dec 03 ’25 when 63781.0 shares were purchased. Officer, WAGNER CHARLES F JR completed a deal on Dec 03 ’25 to buy 7000.0 shares. Meanwhile, Officer WAGNER CHARLES F JR bought 7000.0 shares on Dec 03 ’25.
